Home > Boards > US Listed > Medical - Healthcare > Iovance BiotherapeutIcs (IOVA)

News: $IOVA Iovance Biotherapeutics to Present New Data

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 24
Posts 3,291
Boards Moderated 0
Alias Born 06/04/18
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:06 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/11/2019 5:16:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 8:00:58 AM
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors GlobeNewswire Inc. - 6/11/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 4:33:06 PM
Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating ... GlobeNewswire Inc. - 5/31/2019 7:00:00 AM
Iovance Biotherapeutics to Participate in Upcoming Conferences in June GlobeNewswire Inc. - 5/31/2019 6:59:00 AM
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Produ... GlobeNewswire Inc. - 5/29/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2019 4:41:21 PM
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patie... GlobeNewswire Inc. - 5/22/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 5:22:37 PM
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs GlobeNewswire Inc. - 5/15/2019 5:27:43 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 5:03:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:09:10 PM
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/7/2019 4:01:00 PM
Iovance Biotherapeutics to Participate in Upcoming Conferences in May GlobeNewswire Inc. - 5/2/2019 7:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/1/2019 5:17:53 PM
Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019 GlobeNewswire Inc. - 5/1/2019 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2019 5:02:40 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/19/2019 4:32:39 PM
Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 Ameri... GlobeNewswire Inc. - 4/3/2019 7:05:00 AM
whytestocks Member Level  Wednesday, 04/03/19 11:40:37 AM
Re: None
Post # of 27 
News: $IOVA Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting

SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new interim data from Cohort 2 of the...

Got this from https://marketwirenews.com/news-releases/iovance-biotherapeutics-to-present-new-data-from-ongoing-studies-of-tumor-infiltrating-lymphocyte-til-therapy-at-2019-american-society-of-clinical-oncology-asco-meeting-7939064.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist